COMPANY
Medeor Therapeutics
Timeline
- Trial start Phase 2/Phase 3: Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants source ↗
- Trial start Phase 2: Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants source ↗
- Trial start —: Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products source ↗
- Trial start Phase 3: Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05010174 | Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products | Not listed | Terminated | May 11, 2022 | Apr 30, 2024 (actual) |
| NCT03363945 | Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants | Phase 3 | Completed | Mar 15, 2018 | Apr 11, 2024 (actual) |
| NCT03605654 | Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants | Phase 2/Phase 3 | Withdrawn | 2024-12 | 2026-09 (estimated) |
| NCT03606746 | Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants | Phase 2 | Withdrawn | 2024-12 | 2025-08 (estimated) |